In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Bicycle Therapeutics, with a price target of $33.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth’s rating is based on Bicycle Therapeutics’ strategic restructuring and promising pipeline developments. The company’s decision to reduce its workforce by 25% and cut costs by approximately 30% is expected to extend its cash runway into 2028, providing a solid financial foundation for future operations. This financial stability is complemented by a strong cash position of $721.5 million as of the end of the second quarter of 2025.
Furthermore, Bicycle Therapeutics is making significant progress with its lead asset, zelenectide pevedotin (zele), which is being evaluated in late-stage clinical trials for metastatic bladder cancer. The upcoming meeting with the FDA to discuss dose selection and the potential for accelerated approval could be a major catalyst for the company. Additionally, the ongoing development of their radioconjugate pipeline, with initial imaging data expected later in 2025, adds to the potential growth prospects. These factors collectively support the Buy rating for Bicycle Therapeutics’ stock.
Ramakanth covers the Healthcare sector, focusing on stocks such as Eton Pharmaceuticals, Corcept Therapeutics, and Unicycive Therapeutics. According to TipRanks, Ramakanth has an average return of 7.4% and a 38.32% success rate on recommended stocks.